Stock Highlights: Ensco plc (NYSE:ESV), Exelon Corporation (NYSE:EXC), The Ensign Group, Inc. (NASDAQ:ENSG), OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Phillips 66 Partners LP (NYSE:PSXP)

Ensco plc (NYSE:ESV) reported Revenues were $828 million in fourth quarter 2015 compared to $1.160 billion a year ago primarily due to a year-over-year decline in reported utilization to 63% from 86% in fourth quarter 2014. Also, the average day rate for the fleet declined to $216,000 from $243,000 a year ago.

Ensco plc (NYSE:ESV) belongs to Basic Materials sector. Its net profit margin is -58.90% and weekly performance is -6.65%. On last trading day company shares ended up at $8.28. Ensco plc (NYSE:ESV) distance from 50-day simple moving average (SMA50) is -28.68%.

The Board of Directors of Exelon Corporation (NYSE:EXC) declared a regular quarterly dividend of $0.31 per share on Exelon’s common stock. The dividend is payable on March 10, 2016, to shareholders of record of Exelon as of 5 p.m. New York Time on Feb. 12, 2016.

Exelon Corporation (NYSE:EXC) shares increased 1.80% in last trading session and ended the day at $31.75. EXC Gross Margin is 55.60% and its return on assets is 3.20%. Exelon Corporation (NYSE:EXC) quarterly performance is 14.50%.

The Ensign Group, Inc. (NASDAQ:ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care, assisted living and urgent care companies, announced that it participated in the RBC Capital Markets 2016 Healthcare Conference on February 23, 2016, in New York, New York.

On 24 February, The Ensign Group, Inc. (NASDAQ:ENSG) shares increased 2.28% and was closed at $19.71. ENSG EPS growth in last 5 year was 2.00%. The Ensign Group, Inc. (NASDAQ:ENSG) year to date (YTD) performance is -12.90%.

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from a Phase 1b clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer. The Phase 1b dose-escalation trial enrolled 27 previously untreated patients with extensive-stage small cell lung cancer to assess the safety, biomarker, and anti-tumor activity of tarextumab in combination with etoposide and platinum-based chemotherapy. Doses of tarextumab ranged from 5 mg/kg to 15 mg/kg and a Phase 2 combination dose of 15mg/kg every three weeks was selected.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) ended the last trading day at $9.50. Company weekly volatility is calculated as 7.26% and price to cash ratio as 1.63. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) showed a weekly performance of -2.56%.

On 17 February, Phillips 66 Partners LP (NYSE:PSXP) announced that it has reached agreement with Phillips 66 (PSX) to acquire a 25 percent controlling interest in Phillips 66 Sweeny Frac LLC, which owns the newly constructed Sweeny Fractionator One and Clemens Caverns storage facility, for total consideration of $236 million. The transaction consideration consists of $24 million in newly issued PSXP units and the assumption of $212 million in notes payable to Phillips 66.

Phillips 66 Partners LP (NYSE:PSXP) shares fell -1.18% in last trading session and ended the day at $60.04. PSXP return on assets is 10.40%. Phillips 66 Partners LP (NYSE:PSXP) quarterly performance is 0.68%.

Leave a Reply

Your email address will not be published. Required fields are marked *